Literature DB >> 7954396

Abnormal expression of perlecan proteoglycan in metastatic melanomas.

I R Cohen1, A D Murdoch, M F Naso, D Marchetti, D Berd, R V Iozzo.   

Abstract

Abnormal expression of proteoglycans has been implicated in cancer and metastasis primarily because these macromolecules are involved in the control of cell growth and matrix assembly. In this report, we have investigated the expression and immunolocalization of perlecan, a major heparan sulfate proteoglycan of basement membranes and pericellular matrices, in human metastatic melanomas. Twenty-six of the 27 tumor samples showed a significant increase (up to 15-fold) in the perlecan mRNA levels when compared with normal tissue. This change correlated with a vast deposition of perlecan protein core in the pericellular matrix of metastatic melanomas. Furthermore, we have established a relationship between perlecan expression in clonal melanoma cells (70W) stimulated with neurotrophins and their increased invasiveness. Interestingly, perlecan mRNA levels were up-regulated within 10 min of neurotrophin stimulation, indicating that perlecan is an early response gene. This upregulation also occurred prior to heparanase production, suggesting that perlecan expression and its regulation might play a pivotal role in the initial onset of invasion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954396

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

Review 2.  The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.

Authors:  Stephen Douglass; Atul Goyal; Renato V Iozzo
Journal:  Connect Tissue Res       Date:  2015-07-16       Impact factor: 3.417

Review 3.  Targeting dormant micrometastases: rationale, evidence to date and clinical implications.

Authors:  Robert E Hurst; Anja Bastian; Lora Bailey-Downs; Michael A Ihnat
Journal:  Ther Adv Med Oncol       Date:  2016-03       Impact factor: 8.168

Review 4.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

5.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

6.  Endorepellin-evoked Autophagy Contributes to Angiostasis.

Authors:  Atul Goyal; Maria A Gubbiotti; Daphney R Chery; Lin Han; Renato V Iozzo
Journal:  J Biol Chem       Date:  2016-07-19       Impact factor: 5.157

7.  Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.

Authors:  Atul Goyal; Chiara Poluzzi; Chris D Willis; James Smythies; Adam Shellard; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

Review 8.  Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions.

Authors:  Andreas Friedl
Journal:  Semin Cell Dev Biol       Date:  2009-11-28       Impact factor: 7.727

Review 9.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

10.  Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells.

Authors:  Chris D Willis; Chiara Poluzzi; Maurizio Mongiat; Renato V Iozzo
Journal:  FEBS J       Date:  2013-02-28       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.